Fish oil N-3 fatty acids increase adiponectin and decrease leptin levels in patients with systemic lupus erythematosus

Cardiovascular disease (CVD) has emerged as an important cause of death in patients with systemic lupus erythematosus (SLE). Reduced adiponectin and elevated leptin levels may contribute to CVD in SLE patients. The purpose of this study was to verify the effects of fish oil (FO) on adiponectin and l...

Full description

Saved in:
Bibliographic Details
Published in:Marine drugs 2015-02, Vol.13 (2), p.1071-1083
Main Authors: Lozovoy, Marcell Alysson Batisti, Simão, Andréa Name Colado, Morimoto, Helena Kaminami, Scavuzzi, Bruna Miglioranza, Iriyoda, Tathiana Veiga Mayumi, Reiche, Edna Maria Vissoci, Cecchini, Rubens, Dichi, Isaias
Format: Article
Language:English
Subjects:
adiponectin
Adiponectin - agonists
Adiponectin - metabolism
Adult
Anthropometry
Biomarkers - metabolism
Blood Pressure
cardiovascular risk
Fatty Acids, Omega-3 - therapeutic use
Female
fish oil
Fish Oils - therapeutic use
Humans
leptin
Leptin - antagonists & inhibitors
Leptin - metabolism
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - metabolism
Male
Marine
Middle Aged
Prospective Studies
systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease (CVD) has emerged as an important cause of death in patients with systemic lupus erythematosus (SLE). Reduced adiponectin and elevated leptin levels may contribute to CVD in SLE patients. The purpose of this study was to verify the effects of fish oil (FO) on adiponectin and leptin in patients with SLE. Biochemical and disease activity analysis were performed. Patients with SLE were divided in two groups: patients who used fish oil for four months and patients who did not use fish oil. Patients with SLE who used FO had a significant decrease in SLE disease activity index (SLEDAI) score (p ˂ 0.023) in relation to baseline. SLE patients who used fish oil had increased adiponectin levels (p ˂ 0.026) and decreased leptin levels (p ˂ 0.024) compared to baseline values, whereas there were no differences in adiponectin and leptin levels in patients with SLE who did not use fish oil. In conclusion, the findings of increased serum adiponectin an decreased leptin levels after 120 days in the fish oil group, reinforce the importance of evaluating prospective studies of fish and fish oil fish ingestion on these adipokines in an attempt to decrease cardiovascular risk factors in patients with SLE.
ISSN:1660-3397
1660-3397
DOI:10.3390/md13021071